CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security? DOI Creative Commons
Xueshuai Ye, Min Ge,

M. Tan

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 4, 2025

CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has achieved marvelous results in the treatment of patients with relapsed and/or refractory B-cell lymphomas, acute lymphoblastic leukemia, and multiple myeloma. As a new method that changed existing paradigm, there been short time from its emergence to FDA approval. However, increasing number cases passage time, hidden problems have gradually exposed. In this review, we summarize short- long-term toxicity, such as secondary tumors lethal CAR tumors, hematologic malignancies treated CD19-CAR-T cells, including cytokine release syndrome (CRS), ICANS, low occurrence rates but high mortality, T cell which may be related gene modification mechanism viral vectors currently approved for CAR-T cells. We also discuss potential investigational strategies designed improve safety CAR-T-cell therapy.

Language: Английский

Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies DOI Open Access
Amanda E. Marinoff,

Allyson Thrall,

Kathryn Aaronson

et al.

Pediatric Blood & Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

ABSTRACT Background Thrombopoietin receptor agonists (TPO‐RAs) have demonstrated efficacy in treating clinically significant thrombocytopenia, including chemotherapy‐induced thrombocytopenia adults. However, data regarding their safety and pediatric, adolescents, young adult (AYA) patients with hematologic malignancies are limited. Methods We retrospectively identified 15 pediatric AYA aged 25 years or younger treated a TPO‐RA at UCSF Benioff Children's Hospitals between 2015 2023. Platelet counts transfusion requirements were compared before after therapy. Results The median age initiation was 16 (range: 7–25 years). Nine (60%) had history of bleeding comorbidity that predisposed to severe risk. Eleven received romiplostim four eltrombopag. platelet count significantly increased from 24 × 10 9 /L baseline 54 3 weeks any therapy ( p = 0.029). Monthly decreased two units 0.007). Fourteen the (93%) achieved sustained >50,000/µL within 8 weeks, time response weeks. No TPO‐RA‐related adverse events observed. Conclusion TPO‐RAs effective managing refractory being for malignancies, favorable profile, even among multiple comorbidities. These findings warrant further investigation through prospective clinical trials confirm establish guidelines this population.

Language: Английский

Citations

0
CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security? DOI Creative Commons
Xueshuai Ye, Min Ge,

M. Tan

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 4, 2025

CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has achieved marvelous results in the treatment of patients with relapsed and/or refractory B-cell lymphomas, acute lymphoblastic leukemia, and multiple myeloma. As a new method that changed existing paradigm, there been short time from its emergence to FDA approval. However, increasing number cases passage time, hidden problems have gradually exposed. In this review, we summarize short- long-term toxicity, such as secondary tumors lethal CAR tumors, hematologic malignancies treated CD19-CAR-T cells, including cytokine release syndrome (CRS), ICANS, low occurrence rates but high mortality, T cell which may be related gene modification mechanism viral vectors currently approved for CAR-T cells. We also discuss potential investigational strategies designed improve safety CAR-T-cell therapy.

Language: Английский

Citations

0